Time-Restricted Eating in Huntington’s Disease: Review of the Literature and a Proposed Clinical Trial
Objective: Review recent literature on time-restricted eating (TRE) in Huntington’s disease (HD) and outline our protocol for an upcoming clinical trial designed to assess the…Physical Activity Levels and Demographic Characteristics in Individuals with Huntington’s Disease: Insights from the ENROLL-HD Database in an Argentinian Movement Disorder Center
Objective: To assess PA levels in individuals enrolled in the ENROLL-HD database, and compare demographic characteristics between PE practitioners, and non-practitioners Background: Neurological disorders have been…Sustained Chorea Improvements with Long-Term, Once-Daily Valbenazine in Adults with Huntington’s Disease
Objective: To present interim analyses from KINECT®-HD2 (NCT04400331), an ongoing open-label study of once-daily valbenazine (VBZ) for chorea associated with Huntington’s disease (HD). Background: In…Treatment Effect Sizes of Once-Daily Valbenazine for Tardive Dyskinesia and for Chorea Associated with Huntington’s Disease: A Post-Hoc Analysis of Phase 3 Clinical Trial Data
Objective: To assess the treatment effect size of once-daily valbenazine for tardive dyskinesia (TD) and for chorea associated with Huntington’s disease (HD) using data from…Deciphering the Huntington’s Disease Research Landscape: A Comprehensive Bibliometric and Trend Analysis
Objective: To map the Huntington's Disease research landscape, identifying key trends, gaps, and the most impactful studies to guide future research directions and therapeutic strategies.…Melatonin for huntington disease (HD) gene carriers with HD-related sleep disturbance – a pilot study
Objective: To evaluate the efficacy of exogenous melatonin in improving sleep quality in Huntington disease (HD) gene carriers. Background: Various sleep disorders have been identified…A minimal clinically important difference for UHDRS® Total Maximal Chorea score as a measure of chorea severity in Huntington disease
Objective: To establish a minimal clinically important difference (MCID) for the Unified Huntington Disease Rating Scale (UHDRS®) Total Maximal Chorea (TMC) score as a measure…Metoclopramide-induced acute dystonic reaction caused by CYP2D6 *4/*4 and CYP2D6 *10/*10 genotypes
Objective: Objective is to demonstrated the role of CYP P450 2D6 polymorphisms in metoclopramide-induced acute dystonic reactions. Background: Metoclopramide can induce acute extrapyramidal reactions by…Deep brain stimulation in chorea: four cases and literature review
Objective: We present four cases of pediatric chorea managed with deep brain stimulation (DBS) and review previously reported cases in the literature. We review clinical…Indirect treatment comparison of valbenazine with deutetrabenazine for improvement in total maximal chorea score in Huntington disease
Objective: To conduct an indirect treatment comparison (ITC) between valbenazine and deutetrabenazine using data from clinical trials in adults with chorea associated with Huntington disease…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 9
- Next Page »